CTD Holdings Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
204.90
592.70
2,551.40
4,223.80
3,833.10
4,255
Depreciation, Depletion & Amortization
148.00
152.40
169.00
107.10
9.30
10.10
Other Funds
21.70
50.00
-
-
-
95.60
Funds from Operations
566.40
280.00
2,046.40
3,078.30
3,702.40
4,149.30
Changes in Working Capital
9.90
351.10
57.00
127.40
639.90
960.90
Net Operating Cash Flow
556.50
631.20
1,989.40
2,950.90
3,062.50
3,188.40
Capital Expenditures
156.90
173.90
419.20
9.30
6.90
Sale of Fixed Assets & Businesses
2.00
-
0.70
924.70
4.70
Net Investing Cash Flow
154.90
173.90
418.50
942.90
32.20
Issuance/Reduction of Debt, Net
134.30
57.30
40.50
754.00
-
Net Financing Cash Flow
155.90
2,916.60
1,870.10
1,126.00
3,341.10
Net Change in Cash
245.70
2,111.50
537.80
882.00
310.80
Free Cash Flow
399.60
805.00
2,408.70
2,960.30
3,069.30
Deferred Taxes & Investment Tax Credit
80.00
-
120.00
-
-
-
Other Sources
-
-
-
27.60
34.40
Change in Capital Stock
-
3,023.90
1,910.60
1,880.00
3,341.10

About CTD Holdings

View Profile
Address
6714 NW 16th Street
Gainesvile Florida 32563
United States
Employees -
Website http://www.ctd-holdings.com
Updated 07/08/2019
CTD Holdings, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The company was founded by C.